Related Experiment Video
Updated: Oct 7, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic
E Sherry1, H Boeck, P H Warnke
1OR Design Unit, University of Sydney, Nepean Hospital, PO Box 63, Penrith, NSW 2750, Australia. esherry@bigpond.com
Background:
Antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE, are an increasing problem world-wide, causing intractable wound infections. Complex phytochemical extracts such as tea tree oil and eucalypt-derived formulations have been shown to have strong bactericidal activity against MRSA in vitro. Polytoxinol (PT) antimicrobial, is the trade name of a range of antimicrobial preparations in solution, ointment and cream form.
Methods:
We report the first use of this drug, administered percutaneously, via calcium sulphate pellets (Osteoset,TM), into bone, to treat an intractable MRSA infection of the lower tibia in an adult male.
Results And Discussion:
Over a three month period his symptoms resolved with a healing response on x-ray and with a reduced CRP.
Insights
A novel treatment using Polytoxinol (PT) antimicrobial delivered via bone pellets successfully resolved a severe methicillin-resistant Staphylococcus aureus (MRSA) bone infection. This approach offers a promising new strategy for intractable bacterial wound infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Biomedical Engineering
Background:
- Antibiotic resistance, exemplified by MRSA and VRE, poses a significant global challenge for wound infections.
- Phytochemicals like tea tree oil and eucalyptus extracts exhibit potent in vitro bactericidal effects against MRSA.
- Polytoxinol (PT) is a novel antimicrobial preparation available in various formulations.
Observation:
- This study details the first percutaneous administration of Polytoxinol (PT) via calcium sulphate pellets (Osteoset) into bone.
- The treatment targeted an intractable methicillin-resistant Staphylococcus aureus (MRSA) infection in the lower tibia of an adult male.
Findings:
- The patient experienced symptom resolution over a three-month treatment period.
- Radiographic evidence indicated a healing response in the affected bone.
- C-reactive protein (CRP) levels, a marker of inflammation, were reduced.
Implications:
- Percutaneous delivery of Polytoxinol (PT) via bone pellets presents a potentially effective method for treating deep-seated bone infections.
- This innovative drug delivery system could offer a new therapeutic avenue for challenging MRSA infections.
- Further research into this localized drug delivery method is warranted for complex osteomyelitis cases.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Hand hygiene
Hand washing...